PLASMA Plus CASE STUDIES
The following reports of patients, who were procured for us by the government of Spain, document the resulting benefits received when the patients were given PLASMA Plus infusions. PLASMA Plus was tested over more than a two year (29 month) period. Testing was supervised by the Lainal Laboratorio Industrial Alimentario, Fuenlabrada (Madrid), Camino Baja de Getafe, Number 5 en el Poligono Industrial Sevilla.
We hope that these reports will be of some help to you in understanding our new process.
Testing Supervised By The:
LAINAL LABORATORIO INDUSTRIAL ALIMENTARIO
Fuenlabrada (Madrid) Camino Bajo de Getafe,
Number 5en el Poligono Industrial Sevilla
______________________________________________________
On March 4, 1997 the patient's weight was 122 lbs. He was standing on his own for up to seven minutes at a time. His blood profiles were still showing the virus, but the effects were lessened and the virus is not as prevalent. Scans revealed the presence of scar tissue on the liver. Treatment continued with titration of the dosage to wean the patient's body from the PLASMA Plus. This weaning allows the body to gradually regenerate and begin to rebuild system defenses.
The weaning period continued through the rest of March and April. The dosages were decreased by one and one half hours per week, approximately.
Update: June 15, 1998 the patient was treated then examined by two medical doctors from the Universidad Hospital of Madrid and myself. The blood profiles revealed liver and kidney functions were within normal limits. Scans revealed the liver had regenerated and there existed only areas of discoloration. These areas were biopsied and found to contain normal liver tissue. No virus could be isolated in the blood. CNS examination was better than we expected. The patient's weight was up to 178 lbs. His skin color was good. The patient was appropriate in his response.
Next follow up of this patient will be June 6, 1999.
_____________________________________________
Experiment: One
October 23, 1996
Testing was begun at 2:30p.m. on our pet, Ben. Ben was, at that time, a 4-month-old experimental rat. For the purposes of this study, we will hereafter refer to Ben as the ‘patient.'
Our patient was introduced to the human immunodeficiency virus (HIV) by means of intravenous injection. The patient was closely watched and studied as the virus slowly took over the immune system and began to destroy his defense systems.
We then began treatment of the patient with the PLASMA Plus formula. The dosage for this experiment was at 1cc/unit per eight hours of intravenous infusion. Observation of the patient for the 72 hours following the introduction of the PLASMA Plus formula revealed: 1] increased movement, 2] increased nutritional consumption, 3] marked increases in strength.
Observation was continued over the next 27 days with maintenance of the intravenous infusion at the same dosages. After the 27 days of treatment with PLASMA Plus, the patient's blood samples contained no sign of the virus.
This experiment and these results were reproduced in four other patients. PLASMA Plus was then introduced to the Madrid Court System.
_____________________________________________
Experiment: Two
Case Number: 1236654
This subject, a 34-year-old female, sustained third degree burns extending from the left side of her neck across her left breast, to the fingers of her right hand. The areas of damage were first cleansed then submerged in PLASMA Plus formula solution. Treatment frequencies were TID x seven days, then twice weekly. Then twice monthly following emersion of the affected areas in the PLASMA Plus solution. The area was wrapped with 2-inch sterile gauze.
After the first 22 days of treatment, the patient was showing faster tissue regeneration and healing of the wounds than other burn cases we have observed. There was no infection. Muscle tissue also exhibited a stronger, healthier response than the other burn cases.
After the 34th day of treatment, the patient was showing 100% healing with no scar tissue.
This was the only exterior study performed with the PLASMA Plus formula.
Comment:: We have seen that using the Plasma Plus formula with burn patients enhances the healing process. Healing occurs much faster, is infection free with minimal, if any, scar tissue present, and with no side effects observe
________________________________________
Experiment: Three
Case Number: 1235593
This subject, a 48-year-old male, was an auto immunodeficiency syndrome (AIDS) patient. The patient's weight at the beginning of treatment was 94 lbs. His height was 5'6". Virus infection status was third level. The patient was informed by the Hospital of Madrid that further treatment would provide no other benefit to him and he was to be discharged and sent home. He agreed to be admitted to our study.
Treatment started February 3, 1997 @ 10:00a.m. at the University Hospital of Madrid. Complete blood profiles were drawn to establish a baseline and assess the level of progress of the disease for ourselves. We found that the virus had affected his liver function markedly and his kidney functions were at minimal levels. The CNS was unresponsive.
Intravenous infusions were begun. First, 1000cc of a combination of Vitamin A, Vitamin C and Vitamin E were given intravenously over an 8-hour period. After these infusions were completed, the patient was allowed to rest. Approximately 30 hours later, the patient exhibited no adverse effects and, in fact, seemed improved with the introduction of the fluids. This opened the door for the usage of our new formula, PLASMA Plus.
We gave the patient an initial dosage over an 8-hour period, let him rest for 36 hours. This was to insure acceptance of the formula by his body systems without side effects. Following observation that the patient had no adverse effects, intravenous infusions were given for eight hours with 36 hour rest periods between treatments.
The patient's response to these treatments was evidenced by increasing levels of consciousness and becoming aware of his environment. He became stronger by the day. After the 7th day, February 14, 1997 @ 11:30 a.m., the patient sat up, unassisted, and requested a meal.
Following continued treatment for another seven days, we once again drew complete blood profiles. Studies were improved, evidenced by improvement in liver and kidney function, but the virus remained. However, the patient's general status was improved. His skin color and tone were much better and he was talking. The following four treatments were the same with some continued good response.
____________________________________________
Experiment Number: Four
Case Number 1235526
The subject, a 44-year-old male with diabetes, was admitted to the study May 13, 1997. As you know, Diabetes Mellitus is the insufficient production of insulin by the pancreas. The patient received biweekly dialysis treatments, as well as being insulin dependent. The patient's height and weight are 5'5" and 224 lbs. Physical examination upon introduction to our study revealed the patient to have blurred vision, advanced pruritus of the upper & lower extremities, polydipsia, excessive drowsiness, obesity, fatigue, skin infection with markedly slow healing of any wound, hypertension (B/P 220/90), and pedal tingling and numbness bilaterally. Lab work was done to establish baseline glucose values.
Treatment commenced on May 15, 1997 with intravenous infusion of PLASMA Plus. at the rate 250cc/hour for eight hours. The patient was then allowed to rest for six hours. At the end of this time period, blood work was done that revealed the patient was still in distress due to pancreas damage, but some favorable changes in blood levels were evident. The patient was allowed to rest for an additional eight hours. Lab work was repeated and showed more noticeable changes in blood levels that indicate the pancreas was beginning to rehabilitate. The PLASMA Plus. treatment was repeated as above and continued for another 3 weeks.
At the end of 3 weeks, blood work was again drawn which revealed the pancreatic values to be near normal. Biopsy was done resulting in normal tissue seen. It was decided to put this patient on oral dosage of PLASMA Plus. with nutritional supplements and herbs.
Update - June 15, 1998: This patient is living an active and full life. Insulin injections were stopped eight months previously, approximately five months after the initial treatments. Dialysis was discontinued seven months previously, approximately six months after initial treatment. The patient reports healing times are normal and that other symptoms of diabetes have gone away. Blood coagulation times were within normal limits. The patient's B/P was 160/70 and his weight was 138 lbs. The patient's visual deficits remain. Ongoing treatment consists of the supplements and herbs.
Follow up of this patient will occur on June 6, 1999.
__________________________________________________
Experiment Number: Five
Case Number: 1235613
This subject, a 28-year-old male with hepatitis, was admitted to our study May 15, 1997. Physical examination reveals the patient's height and weight to be 6'0" and 128 lbs., respectively. The patient's skin exhibited jaundice. Biopsy of the liver showed inflammation. Other findings of an initial physical exam included fever, weakness, nausea, vomiting, muscle aches, drowsiness, headache and abdominal discomfort.
Treatment with PLASMA Plus. Intravenous infusions began May 22, 1997 with 250cc/hour for eight hours. The patient was allowed to rest for 72 hours. Treatment was continued with another 250cc/hour dosage over eight hours. This treatment allows the body to flush the liver and potentiates regeneration of liver tissue. The patient was again allowed to rest for 72 hours.
Treatment continued for six weeks. A second physical exam was done which revealed liver function much improved. The healing evidenced by these improved lab values surprised even us. After the third treatment, we began forcing fluids on this patient plus one tablespoon of olive oil and 6 ounces of lemon juice. This flushing treatment continues 3 times per week for four weeks. PLASMA Plus. Formula treatments continued as above until June 30, 1997. At that time, treatment with PLASMA Plus. Formula was discontinued. Lab values show liver function within normal limits. Although the liver continues to show discoloration, biopsy revealed normal liver tissue.
Update - June 17, 1998. This patient works and lives a normal life with no problems. The patient continues to flush on his own. He consumes a regular diet and exercises regularly.
Follow up of this patient will occur June 10, 1999.
MARKETING OF THE PLASMA PLUS TREATMENT::
Marketing of the PLASMA Plus Treatment is being considered through the following options:
1: PUBLIC OFFERING.
The company is studying the feasibility of taking the company public through an IPO to raise the funding for world-wide distribution of the PLASMA Plus product.
It is believed that the successful demonstration of the PLASMA Plus product and its ability to reverse the HIV process and rid the body of the virus, up to and including advancement into the stages of AIDS, will give sufficient impetus for the company to raise the funding it needs through an IPO to market the product on a world-wide basis.
This scenario would enable the company to keep full control of the product and set up distribution networks to handle the blanket marketing of the product on a global level.
This multi-national approach would create a pipe-line for funding as needed both for speedier manufacturing and distribution as well as for additional research into other areas of public interest and need.
2: PRIVATE FUNDING.
Exploratory discussions with individual investors, corporations or foundations interested in obtaining the rights to the PLASMA Plus formula and the subsequent distribution rights will be entertained to ascertain if this is in the best interest of the company.
Private investors wishing to take over the company and set up their own manufacturing and distribution networks through a cash buyout to be worked out between thre parties.
The company may wish to retain a portion of the stock in the company as a future ‘annuity.'
3: STOCK PURCHASE.
The Company would entertain the proposal of a stock purchases for:
1: The entire company for stock, and/or stock plus other incentives as part of the package such as warrants or options, or,
2: A combination of cash , stock and/or incentives.
Large pharmaceutical companies would be prime candidates due to the synergistic involvement and their overall ability to market the product more effectively due to their own marketing capabilities as well as through their distribution channels already in place.
4: GOVERNMENT FUNDING.
The company is looking into the feasibility of dealing on a State level for government purchases to aid in the distribution of the PLASMA Plus treatment on a national basis, especially where the overall incidence of HIV and AIDS has reached virtually epidemic proportions.
The company believes that mass distribution can be effective as the economies of scale would make it practical to provide the Treatments on an broad national economic level.
5: ORGANIZATIONAL FUNDING.
Organizations such as the World Health Organization (WHO), the United Nations through its various agencies, The Red Cross and the International Monetary Fund (IMF) would see the feasibility of making loans to countries where its health sector is particularly vulnerable to epidemics of this type.
6: LICENSE AGREEMENTS.
Individual Country-by-Country license agreements could be worked out with entities in a position to remunerate the company for the right to license on a Country-by-Country basis.
The License agreements would cover:
1. Specific payment methods for obtaining the License Agreements.
2. Countries covered by the License Agreement.
3. Performance figures tied into the cost of the treatments vils.
4. Time frames for reaching performance figures.
5. Negotiation rights to additional License Agreements.
7: JOINT VENTURE.
Another area of interest for the company would be a joint venture with a partner in both a financial and marketing position to make it feasible to structure a joint venture relationship and maintain the individual identities of the joint venture partners.
8: LOAN.
A loan from a government or world organization, based on the merits of the PLASMA Plus formula would allow the company to move ahead with its other options and begin to market the treatment on a broad level.
Background / Research:
ALFRED FLORES
DOB: June 6, 1950
Saville, Spain
Educational
Background: High School: Graduated: Delta High School - 1964 Delta, Colorado
College: Regis College - Colorado Springs, CO. - 2 Years
University of Colorado - Boulder, Co. - 4 Years
University Of Madrid - Madrid, Spain - 4 Years
Degrees: Associate & Associate of Science - Regis College
Bachelor Of Science - Chemistry - University of Colorado
Masters of Science - Pharmaceutical Research - University of Madrid - With Honors
Major : Pharmaceutical Minor : Robotics
Experience:
1972 - 1978 American Laboratories, Santa Rosa, California
Government Projects
Researching new methods and confirming of newly developed medications
1979 - 1982 Fort Lewis Laboratories, Olympia, Washington
Research and Development
Additional work and research into areas newly developed medications
1982 - 1992 Panrac Chemicals / Bayers, Headquarters - Madrid, Spain
Chemical Analyzer - Research
Verification of exit dosages of developed products
1992 - Present Research on Plasma Plus Project
Research: Mr. Flores' began his private research in the field of immunology at his own laboratory located just outside of Lisbon, in Portugal. The laboratory was privately funded by Mr. Flores.
His work was carried out with a team of sixteen with backgrounds predominantly in the field of chemistry, along with the assistance of three distinguished professors from the University of Spain: Dr. Moya, Professor Fuentes and Professor Castro.
Research was initially carried out in the field of immunology. This led to the further exploration into CD counts of the HIV virus and the lack of transference from a mother to fetus when the mother was infected up to the point of reaching the stage of fully developed AIDS. This further led to other areas of research where the HIV virus was concerned.
The Plasma Plus formula evolved along with the research being done in the general areas of immunology. It was being developed to build up the entire immune system to general viruses in the body.
The discovery of the effects of The Plasma Plus on HIV actually took place on November 8, 1994 when the introduction of the Plasma Plus formula led to the discovery that the bone marrow of one of the patients was producing up to 3X the amount of red blood cells per cm3 of the average person that translated into more oxygen into the blood. It also was therefore producing higher white cell count per cm3 for fighting infection. This resulted in a higher level of immunity due to the superior number and therefore effectiveness of the white blood cells. By the overpowering of the HIV viruses by these stronger white cells, it stopped the virus from successfully attacking the white cells and being able to survive and reproduce. Once the virus was weakened in the white cells, it could no longer sustain itself and was discarded along with the white cells.
Additional testing on HIV and AIDS patients from that point on further validated the ability of the Plasma Plus to reverse the effects of the HIV and AIDS stages and return the patient to normal CD4+ T-cell levels.
|
